For how we live.
In the NSABP B-59 trial, adding the immunotherapy to neoadjuvant chemotherapy did not significantly improve event-free survival, while immune-related side effects more than doubled.
Dense tissue raises breast-cancer risk and hides cancers on a mammogram. US facilities must now tell patients — but the evidence on what to do next is a real trade-off: more cancers found, more false alarms.
SleepCARE randomised 219 Australian women receiving chemotherapy for breast cancer to CBT-I, bright light therapy, both, or sleep hygiene. Only CBT-I moved insomnia — and nothing moved fatigue.
Six products got revised labels in February 2026, removing cardiovascular, breast cancer, and dementia language. The scientific societies that welcomed the change also listed the distinctions the new label does not make.
US guidance recommends mammography from 40. A Canadian review of the same randomised evidence put the benefit at 0.27 fewer breast cancer deaths per 1,000 women aged 40-49 over ten years.
The IARC calls night shift work probably carcinogenic. A 2026 meta-analysis of nurses shows why 'probably' is careful: the breast cancer signal appears only after decades, and shrinks to nothing once bias is corrected.
A comparative survey finds four European countries still rely on opportunistic screening, and that where family doctors are most involved, participation tends to be lower — not higher.
The VEMORA trial randomized 23 women with genitourinary symptoms. Vaginal estrogen improved dryness and pain scores more than Replens, with blood estrogen staying low.
A Finnish registry of over 123,000 women found pre-eclampsia linked to an 11% lower breast cancer risk decades later. Hormone therapy raised risk by a similar amount in both groups.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
An age-period-cohort analysis across five registries finds annual increases of 5.3% in Korea and 3.8% in Japan, against 1.6% among Japanese Americans and flat or falling rates in US White women.
Women whose habits aligned with a favorable estrogen-metabolism pathway had up to 61% lower endometrial cancer risk. The score explains only a tenth of the variation it predicts.
Pooling decades of research, the combined estrogen-progestin regimen showed a 44% higher breast cancer risk. Estrogen-only therapy showed none in observational studies — and trials suggested it lowered risk.
A Taiwanese cohort of 26,000 women aged 20 to 50 puts numbers on a known tamoxifen risk in a population — younger, premenopausal — where data has been thinner.
In 105,260 people followed for 7.6 years, higher intakes of sorbates, sulfites, nitrates and acetates tracked with modestly higher cancer incidence. This is an observational study of self-reported diets.
The consensus statement does not claim the treatment is safe after breast cancer. It says some women may reasonably accept an increased relapse risk in exchange for symptom relief.
WISDOM randomised 28,372 women to annual mammography or a risk-tailored schedule. The risk-based arm met its non-inferiority mark for advanced cancers — with caveats about who enrolled.
VENUSCANCER assembled individual records for 275,792 women from 103 cancer registries in 39 countries. The gaps it found are in what treatment women actually received, not only in whether they were diagnosed.
Age-standardised incidence was 42.3 per 100,000 in Ghana and 43.1 in US non-Hispanic Black women, against 24.0 in white women. ER-positive rates diverged sharply in the other direction.